Solid Biosciences Inc. – NASDAQ:SLDB
Founder-led company
Solid Biosciences stock price today
$5.85
+1.60
+37.97%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Solid Biosciences stock price monthly change
-46.40%
month
Solid Biosciences stock price quarterly change
-46.40%
quarter
Solid Biosciences stock price yearly change
-34.97%
year
Solid Biosciences key metrics
Market Cap | 160.80M |
Enterprise value | N/A |
P/E | -0.48 |
EV/Sales | -5.29 |
EV/EBITDA | 0.64 |
Price/Sales | 2.53 |
Price/Book | 0.19 |
PEG ratio | -1.17 |
EPS | -3.94 |
Revenue | N/A |
EBITDA | -97.59M |
Income | -90.24M |
Revenue Q/Q | N/A |
Revenue Y/Y | -66.79% |
Profit margin | -842.61% |
Oper. margin | -971.13% |
Gross margin | 38.11% |
EBIT margin | -971.13% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSolid Biosciences stock price history
Solid Biosciences stock forecast
Solid Biosciences financial statements
| Jun 2023 | 0 | -24.62M | |
|---|---|---|---|
| Sep 2023 | 0 | -20.98M | |
| Dec 2023 | 4.73M | -20.33M | -429.39% |
| Mar 2024 | 0 | -24.30M |
| Sep 2025 | 0 | -15.43M | |
|---|---|---|---|
| Oct 2025 | 0 | -28.61M | |
| Dec 2025 | 0 | -30.33M | |
| Mar 2026 | 0 | -24.78M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 204721000 | 40.99M | 20.02% |
|---|---|---|---|
| Sep 2023 | 184728000 | 40.36M | 21.85% |
| Dec 2023 | 164939000 | 38.45M | 23.32% |
| Mar 2024 | 248689000 | 37.96M | 15.27% |
| Jun 2023 | -27.46M | -48.23M | 2.61M |
|---|---|---|---|
| Sep 2023 | -17.89M | -24.63M | 0 |
| Dec 2023 | -20.82M | 45.29M | 505K |
| Mar 2024 | -25.19M | -38.49M | 107.24M |
Solid Biosciences alternative data
| Aug 2023 | 87 |
|---|---|
| Sep 2023 | 87 |
| Oct 2023 | 87 |
| Nov 2023 | 87 |
| Dec 2023 | 87 |
| Jan 2024 | 87 |
| Feb 2024 | 87 |
| Mar 2024 | 88 |
| Apr 2024 | 88 |
| May 2024 | 88 |
| Jun 2024 | 88 |
| Jul 2024 | 88 |
Solid Biosciences other data
19.82%
-80.18%
of SLDB is owned by hedge funds
18
-16
1.68M
-13.62M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 4314873 | 5216 |
| May 2024 | 0 | 462 |
| Jun 2024 | 1100 | 0 |
| Oct 2024 | 0 | 2923 |
| Dec 2024 | 0 | 23573 |
| Quarter | Transcript |
|---|---|
| Q1 2022 30 Apr 2022 | Q1 2022 Earnings Call Transcript |
| Q1 2021 14 May 2021 | Q1 2021 Earnings Call Transcript |
Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
Buy Solid Biosciences: Unpacking Its Main Value Driver
Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid
Regenxbio: A Transformative Year
Pfizer: New Potential Billion-Dollar Drugs Under Development
Regenxbio: Is The Ultimate Catalyst Coming?
Sarepta: Still A Solid Long-Term Bet On Sales And Next Generation Treatments
-
What's the price of Solid Biosciences stock today?
One share of Solid Biosciences stock can currently be purchased for approximately $5.85.
-
When is Solid Biosciences's next earnings date?
Unfortunately, Solid Biosciences's (SLDB) next earnings date is currently unknown.
-
Does Solid Biosciences pay dividends?
No, Solid Biosciences does not pay dividends.
-
How much money does Solid Biosciences make?
Solid Biosciences has a market capitalization of 160.80M.
-
What is Solid Biosciences's stock symbol?
Solid Biosciences Inc. is traded on the NASDAQ under the ticker symbol "SLDB".
-
What is Solid Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Solid Biosciences?
Shares of Solid Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Solid Biosciences's key executives?
Solid Biosciences's management team includes the following people:
- Mr. Ilan Ganot Co-founder, Pres, Chief Executive Officer & Director(age: 51, pay: $829,250)
- Dr. Carl Ashley Morris Chief Scientific Officer(age: 55, pay: $547,400)
- Mr. Matthew Bennett Arnold Co-Founder & Board Member(age: 55, pay: $42,500)
-
Is Solid Biosciences founder-led company?
Yes, Solid Biosciences is a company led by its founders Mr. Ilan Ganot and Mr. Matthew Bennett Arnold.
-
How many employees does Solid Biosciences have?
As Jul 2024, Solid Biosciences employs 88 workers.
-
When Solid Biosciences went public?
Solid Biosciences Inc. is publicly traded company for more then 7 years since IPO on 26 Jan 2018.
-
What is Solid Biosciences's official website?
The official website for Solid Biosciences is solidbio.com.
-
Where are Solid Biosciences's headquarters?
Solid Biosciences is headquartered at 141 Portland Street, Cambridge, MA.
-
How can i contact Solid Biosciences?
Solid Biosciences's mailing address is 141 Portland Street, Cambridge, MA and company can be reached via phone at +61 73374680.
Solid Biosciences company profile:
Solid Biosciences Inc.
solidbio.comExchange:
NASDAQ
Full time employees:
88
Industry:
Biotechnology
Sector:
Healthcare
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
141 Portland Street
Cambridge, MA 02139
Cambridge, MA 02139
CIK: 0001707502
ISIN: US83422E2046
CUSIP: 83422E105
